Amoxycillin products were evaluated for quality by liquid chromatography at the Drug Analysis and Research Unit (DARU), University of Nairobi. Thirty three of these were capsule formulations and 24 were dry suspensions. Three capsule formulations failed the limits on content. The amoxycillin content in one suspension product was below the limit, while in two other products it dropped below 80% on storage at 25°C for 7 days.
INTRODUCTION
a content of 87.0% amoxycillin on an anhydrous basis when assayed against amoxycillin Amoxycillin is a semisynthetic penicillin used trihydrate BPCRS B~~~. , N~. 1487 CAT. 019, in the management of infections caused by sensitive organisms infections especially those ~h , amoxycillin preparations evaluated were causing pneumonia, URTI, UTI and soft tissue obtained through the office of Registrar, infections. It is incorporated in the Ministry of pharmacy and poisons ~~~~d , ~i~ of Health essential drugs list [I] .
Health, Kenya, or were commercial packs
Marketing of poor quality drugs is a major concern in most developing countries and has been widely reported in Africa and elsewhere [2-51. In particular, the use of antibiotic preparations of poor quality could be a contributory factor to failure of therapy. The presence of poor quality penicillin products in the Kenyan market has been reported previously [6- 91. This observation was recently reinforced by the findings on the quality of ampicillin preparations [lo] .
This paper reports on the findings on the quality of amoxycillin capsules and dry syrups found on the Kenyan market during the 10 year period 1994 -2004 using high pressure liquid chromatography (HPLC). The preparations were from private and public sources including those submitted to the Ministry of Health drug regulatory authority, the Pharmacy and Poisons Board. The latter are intended for market in Kenya after registration, and for the purpose of this paper are treated as being on the market. 
EXPERIMENTAL

Samples and standards
Reagents and solvents
HPLC grade acefbnitrile was purchased from Rathburn chemicals (Walkerbum, Scotland, U.K.). Analytical grade, K2HP04 and KH2P04 salts for preparation of buffer were from Acros Organics (New Jersey, USA).
Instrumentation
The liquid chromatographic system consisted of Varian 9010 solvent delivery system, a Varian Variable wavelength UVNisible detector (Varian Associates, Inc., Walnut Creek, USA) set at 254nm, a Valco model CV-6-UHPa-N60 58 Kamau er a/. , East and Cent. Afr. J. Pharm. Sci. 6(2003) sampling valve (Valco, Houston, Texas, USA) equipped with a 25 p1 loop and a Hewlett Packard HP 3396 integrating recorder (Hewlett Packard, Avondale, PA, U.S.A.). A HPLC column of dimensions 25 cm x 4.6 mm packed with RSil C18 10 pm (BioRad RS, Eke, Belgium) was used and was maintained at 40 OC using a water bath.
METHOD Mobile phase
The mobile phase consisted of 0.01 M phosphate buffer pH 7.0 -acetonitrile (97: 3 VIV) and was degassed by ultrasonication before use. The flow rate was set at 1.0 mllmin.
Amoxycillin standard solution
About. 125 mg amoxycillin standard was accurately weighed into a 10.0 ml volumetric flask, dissolved in, and made to volume with distilled water. An aliquot (2.0 ml) of this solution was diluted to 25.0 ml with distilled water in a volumetric flask.
Amoxycillin sample solution
Capsules: Powder equivalent to 125 mg amoxycillin accurately weighed was dissolved in distilled water as completely as possible, to make 100.0 ml in a volumetric flask. This solution was filtered though a 0.45 mm membrane filter and 4.0 ml of the filtrate made to volume with distilled water in a 25.0 ml volumetric flask.
Dry suspensions:
Powder for amoxycillin suspensions was reconstituted with distilled water according to the manufacturer's label instructions. The reconstituted volume of the suspension was determined after sonication to remove air bubbles. A volume of suspension equivalent to 125 mg amoxycillin was pipetted into a 100.0 ml volumetric flask, rinsing the pipette with water. The volume was made to the mark with water and filtered through a 0.45 mm membrane filter. An aliquot (4.0 ml) of the filtrate was used to prepare the sample solution as described for the standard solution.
RESULTS AND DISCUSSION
The content of active ingredient of some 33 amoxycillin capsule formulations were evaluated and are shown in Table 1 . East and Cent. Afr. J. Pharm. Sci. 6(2003) Table 2 shows the amoxycillin content as determined on day 0 and day 7 for the 24 different amoxycillin suspensions . examined. One product, SVII was far below the lower limit of 80% specified by the pharmacopoeia. On storage for 7 days at 25°C the amoxycillin content of SXb and SXla fell below the acceptable limit of 80%. The content of SXla fell drastically from 107.8% to 44.1% of the label claim. The content of amoxycillin in all the products examined changed within the 7 days. Amoxycillin suspensions are normally buffered to maintain stability once reconstituted. The products that failed to comply with the 7-day limit were probably not appropriately buffered. The content of amoxycillin in oral suspensions is specified not to exceed 120% label claim on reconstitution. However, on storage for 7 days, any drop in content should not be lower than 80% of the label claim (1 I).
In this regard products SVII, SXb and SXIa failed the requirements. The manufacturers of products SXb and SXIa are also the manufacturers of products SXa and SXIb respectively, which passed the requirements. One was a local and the other a foreign manufacturer.
There is therefore need for manufacturers to pay attention to such batch to batch variations that may arise and identify causes for them, for example a less than optimum buffering system.
The use of poor quality products, especially antibiotics, such as amoxycillin, can have serious consequences including development of drug resistance and therapeutic failure.
The results of this study support the continuing need for quality certification before and marketing surveillance after products are released into the market by reputable laboratories.
